Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00099_DB01030_nanopub.RAeFq6b6QXDo7qZgssZAIol_dhT4d8gmAtyG0LY3I6o-U#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00099_DB01030 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00099_DB01030 label "DDI between Filgrastim and Topotecan - Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia. [drugbank_resource:DB00099_DB01030]" assertion.
- drugbank_resource:DB00099_DB01030 identifier "drugbank_resource:DB00099_DB01030" assertion.
- drugbank_resource:DB00099_DB01030 title "DDI between Filgrastim and Topotecan - Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia." assertion.
- drugbank:DB01030 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00099_DB01030 assertion.
- drugbank:DB00099 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00099_DB01030 assertion.